• Earnings Per Share (EPS) of $0.37, significantly surpassing the estimated $0.18.
• Revenue of approximately $228.9 million, exceeding the estimated $205.8 million.
• Low debt-to-equity ratio of 0.06 and a current ratio of 3.43, indicating strong financial health.

Varex Imaging Corporation (NASDAQ:VREX), a key player in the medical products industry, specializes in imaging components crucial for medical diagnostics. Competing in the medical imaging sector, Varex strives to deliver innovative solutions and has recently reported strong financial results, showcasing its robust performance.

On November 18, 2025, VREX reported earnings per share (EPS) of $0.37, significantly surpassing the estimated $0.18. This marks an earnings surprise of over 105%, as highlighted by Zacks. The company also reported a revenue of approximately $228.9 million, exceeding the estimated $205.8 million. This revenue figure represents a 3.83% increase over the Zacks Consensus Estimate.

Varex Imaging has consistently outperformed consensus EPS estimates over the past four quarters. In the previous quarter, the company delivered an EPS of $0.18, against an anticipated $0.04, resulting in a remarkable 350% surprise. This consistent performance underscores Varex's ability to exceed market expectations and deliver strong financial results.

The company's financial health is further supported by its low debt-to-equity ratio of 0.06, indicating a low level of debt compared to its equity. Additionally, Varex's current ratio of 3.43 suggests a strong liquidity position, with more than three times the current assets to cover its current liabilities. This financial stability positions Varex well for future growth and development.

Varex's price-to-sales ratio of 0.58 suggests that the stock is valued at approximately 58 cents for every dollar of sales. The enterprise value to sales ratio of 0.45 implies that the company's total valuation is less than its annual sales, highlighting potential investment opportunities.